JP2017502073A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502073A5 JP2017502073A5 JP2016545983A JP2016545983A JP2017502073A5 JP 2017502073 A5 JP2017502073 A5 JP 2017502073A5 JP 2016545983 A JP2016545983 A JP 2016545983A JP 2016545983 A JP2016545983 A JP 2016545983A JP 2017502073 A5 JP2017502073 A5 JP 2017502073A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- dihydro
- methyl
- alkyl
- benzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 8
- -1 amino, substituted amino, aminosulfinyl Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 238000009825 accumulation Methods 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- PWIHPHVXDPLHFA-UHFFFAOYSA-N 1-(6-methyl-2,3-dihydro-1,4-benzoxazin-4-yl)-2-(4-methylpiperazin-1-yl)ethanone Chemical compound CC1=CC2=C(OCCN2C(CN2CCN(CC2)C)=O)C=C1 PWIHPHVXDPLHFA-UHFFFAOYSA-N 0.000 claims 1
- UDVOITWXDYRCKU-UHFFFAOYSA-N 1-(6-methyl-2,3-dihydro-1,4-benzoxazin-4-yl)-2-(4-phenylpiperazin-1-yl)ethanone Chemical compound CC1=CC2=C(OCCN2C(CN2CCN(CC2)C2=CC=CC=C2)=O)C=C1 UDVOITWXDYRCKU-UHFFFAOYSA-N 0.000 claims 1
- HHJYJIJEIOPVOL-UHFFFAOYSA-N 1-(6-methyl-2,3-dihydro-1,4-benzoxazin-4-yl)-2-(4-propan-2-ylpiperazin-1-yl)ethanone Chemical compound CC=1C=CC2=C(N(CCO2)C(CN2CCN(CC2)C(C)C)=O)C1 HHJYJIJEIOPVOL-UHFFFAOYSA-N 0.000 claims 1
- SRHOPNLKQKJWGE-UHFFFAOYSA-N 1-(6-methyl-2,3-dihydro-1,4-benzoxazin-4-yl)-2-morpholin-4-ylethanone Chemical compound CC1=CC2=C(OCCN2C(CN2CCOCC2)=O)C=C1 SRHOPNLKQKJWGE-UHFFFAOYSA-N 0.000 claims 1
- KGVHKLONKNTRGM-UHFFFAOYSA-N 1-(6-methyl-2,3-dihydro-1,4-benzoxazin-4-yl)-2-piperazin-1-ylethanone Chemical compound CC1=CC2=C(OCCN2C(CN2CCNCC2)=O)C=C1 KGVHKLONKNTRGM-UHFFFAOYSA-N 0.000 claims 1
- LGPOHLFVYRMAIB-UHFFFAOYSA-N 1-[4-(2-hydroxyethyl)piperazin-1-yl]-2-(6-methyl-2,3-dihydro-1,4-benzoxazin-4-yl)ethanone Chemical compound OCCN1CCN(CC1)C(CN1CCOC2=C1C=C(C=C2)C)=O LGPOHLFVYRMAIB-UHFFFAOYSA-N 0.000 claims 1
- OJDIUFKGKYDYPL-UHFFFAOYSA-N 1-[4-(2-methoxyethyl)piperazin-1-yl]-2-(6-methyl-2,3-dihydro-1,4-benzoxazin-4-yl)ethanone Chemical compound COCCN1CCN(CC1)C(CN1CCOC2=C1C=C(C=C2)C)=O OJDIUFKGKYDYPL-UHFFFAOYSA-N 0.000 claims 1
- RVZOUOLVWDZPGJ-UHFFFAOYSA-N 2-(4-acetylpiperazin-1-yl)-1-(6-methyl-2,3-dihydro-1,4-benzoxazin-4-yl)ethanone Chemical compound C(C)(=O)N1CCN(CC1)CC(=O)N1C2=C(OCC1)C=CC(=C2)C RVZOUOLVWDZPGJ-UHFFFAOYSA-N 0.000 claims 1
- ZAICYLWSHOUIQW-UHFFFAOYSA-N 2-(4-cyclohexylpiperazin-1-yl)-1-(6-methyl-2,3-dihydro-1,4-benzoxazin-4-yl)ethanone Chemical compound C1(CCCCC1)N1CCN(CC1)CC(=O)N1CCOC2=C1C=C(C=C2)C ZAICYLWSHOUIQW-UHFFFAOYSA-N 0.000 claims 1
- IDZUBCSBBQHFMA-UHFFFAOYSA-N 2-(6-methyl-2,3-dihydro-1,4-benzoxazin-4-yl)-1-(4-methylpiperazin-1-yl)ethanone Chemical compound CC1=CC2=C(OCCN2CC(=O)N2CCN(CC2)C)C=C1 IDZUBCSBBQHFMA-UHFFFAOYSA-N 0.000 claims 1
- ZBYCDFKRVRLSEI-UHFFFAOYSA-N 6-methyl-4-[2-(4-methylpiperazin-1-yl)ethyl]-2,3-dihydro-1,4-benzoxazine Chemical compound CN1CCN(CCN2CCOC3=C2C=C(C)C=C3)CC1 ZBYCDFKRVRLSEI-UHFFFAOYSA-N 0.000 claims 1
- NDGVSTADYFEGTM-UHFFFAOYSA-N N-[2-[4-[2-(6-methyl-2,3-dihydro-1,4-benzoxazin-4-yl)acetyl]piperazin-1-yl]ethyl]methanesulfonamide Chemical compound CC1=CC2=C(OCCN2CC(=O)N2CCN(CCNS(C)(=O)=O)CC2)C=C1 NDGVSTADYFEGTM-UHFFFAOYSA-N 0.000 claims 1
- 125000004442 acylamino group Chemical group 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000001091 aminosulfinyl group Chemical group [H]N([H])S(*)=O 0.000 claims 1
- 125000004682 aminothiocarbonyl group Chemical group NC(=S)* 0.000 claims 1
- 210000001130 astrocyte Anatomy 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 210000000274 microglia Anatomy 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 230000007356 neuronal autophagy Effects 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 0 C*1*N(C)CCN(*)CC1 Chemical compound C*1*N(C)CCN(*)CC1 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461925619P | 2014-01-09 | 2014-01-09 | |
| US61/925,619 | 2014-01-09 | ||
| US201461927911P | 2014-01-15 | 2014-01-15 | |
| US61/927,911 | 2014-01-15 | ||
| PCT/US2015/010690 WO2015106025A1 (en) | 2014-01-09 | 2015-01-08 | Substituted benzoxazine and related compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017502073A JP2017502073A (ja) | 2017-01-19 |
| JP2017502073A5 true JP2017502073A5 (enExample) | 2018-02-15 |
| JP6510539B2 JP6510539B2 (ja) | 2019-05-08 |
Family
ID=53524338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016545983A Expired - Fee Related JP6510539B2 (ja) | 2014-01-09 | 2015-01-08 | 置換ベンゾオキサジン及び関連化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10087151B2 (enExample) |
| EP (1) | EP3091984B1 (enExample) |
| JP (1) | JP6510539B2 (enExample) |
| CA (1) | CA2935944A1 (enExample) |
| WO (1) | WO2015106025A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218850D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| CN115368356B (zh) | 2013-12-20 | 2025-05-09 | 阿斯特克斯治疗有限公司 | 双环杂环化合物及其治疗用途 |
| JP6510539B2 (ja) * | 2014-01-09 | 2019-05-08 | ザ ジェイ． デヴィッド グラッドストーン インスティテューツ， ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デヴィッド グラッドストーン | 置換ベンゾオキサジン及び関連化合物 |
| GB201504064D0 (en) | 2015-03-10 | 2015-04-22 | Accretion Biotechnology Ltd | Method and kits for preparing radionuclide complexes |
| JO3637B1 (ar) | 2015-04-28 | 2020-08-27 | Janssen Sciences Ireland Uc | مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv |
| TWI730980B (zh) | 2015-08-26 | 2021-06-21 | 比利時商健生藥品公司 | 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物 |
| US20190112317A1 (en) | 2015-10-05 | 2019-04-18 | The Trustees Of Columbia University In The City Of New York | Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies |
| US10898504B2 (en) | 2016-03-10 | 2021-01-26 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as PRMT5 inhibitors |
| GB201610956D0 (en) * | 2016-06-23 | 2016-08-10 | Takeda Pharmaceuticals Co | Novel compounds |
| BR112019006414A2 (pt) | 2016-10-03 | 2019-06-25 | Janssen Pharmaceutica Nv | análogos de carbanucleosídeos de sistema de anel monocíclico e bicíclico substituídos para uso como inibidores de prmt5 |
| SG11201907607VA (en) | 2017-02-27 | 2019-09-27 | Janssen Pharmaceutica Nv | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor |
| GB2568549A (en) * | 2017-11-21 | 2019-05-22 | Univ Leicester | New compounds and uses |
| TW201932470A (zh) | 2017-11-29 | 2019-08-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 具有抗ｒｓｖ活性之吡唑并嘧啶 |
| MX2020005944A (es) | 2017-12-08 | 2020-08-24 | Janssen Pharmaceutica Nv | Analogos espirobiciclicos novedosos. |
| CA3087926A1 (en) | 2018-01-31 | 2019-08-08 | Janssen Sciences Ireland Unlimited Company | Cycloalkyl substituted pyrazolopyrimidines having activity against rsv |
| AU2019260109B2 (en) | 2018-04-23 | 2023-07-13 | Janssen Sciences Ireland Unlimited Company | Heteroaromatic compounds having activity against RSV |
| JP7337174B2 (ja) | 2018-09-18 | 2023-09-01 | ニカング セラピューティクス， インコーポレイテッド | Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用ｐｒｍｔ５抑制劑治療癌症之方法 |
| WO2021030537A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| CR20220170A (es) | 2019-10-11 | 2022-10-10 | Incyte Corp | Aminas bicíclicas como inhibidoras de la cdk2 |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| EP4277894A1 (en) | 2021-01-15 | 2023-11-22 | Beckley Psytech Limited | Tryptamine analogues |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB921315A (en) | 1958-03-31 | 1963-03-20 | Wellcome Found | The manufacture of 8-aminoalkylamino quinoline derivatives |
| CH501658A (de) * | 1966-08-11 | 1971-01-15 | Knoll Ag | Verfahren zur Herstellung von N-Aminoacyl-3,4-dihydro-(2H)-1,4-benzoxazinen |
| DE1595863C3 (de) | 1966-08-11 | 1978-03-02 | Knoll Ag, 6700 Ludwigshafen | 4-Piperidinoacetyl-3,4-dihydro-(2H)-l,4-benioxazin und Verfahren zu dessen Herstellung |
| GB1173942A (en) * | 1967-06-06 | 1969-12-10 | Bellon Labor Sa Roger | New 2,3-Dihydro-1,4-Benzoxazines |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| DE3204153A1 (de) | 1982-02-06 | 1983-08-11 | Dr. Karl Thomae Gmbh, 7950 Biberach | Substituierte thienobenzodiazepinone, verfahren zu ihrer herstellung und sie enthaltende arzneimittel |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5652363A (en) | 1995-10-05 | 1997-07-29 | C.D. Searle & Co. | Pyrido-1,4-oxazinylalkyl-benzamide derivatives |
| US6084098A (en) * | 1999-02-26 | 2000-07-04 | Neurogen Corporation | Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands |
| DE19934432A1 (de) | 1999-07-22 | 2001-02-01 | Merck Patent Gmbh | Indolderivate |
| CA2468861C (en) | 2001-12-05 | 2012-06-12 | The Regents Of The University Of California | Robotic microscopy systems |
| UA76877C2 (uk) | 2002-05-13 | 2006-09-15 | Ф.Хоффманн-Ля Рош Аг | Похідні бензоксазину як 5-нт6 модулятори і їх застосування |
| JP2005530800A (ja) | 2002-05-15 | 2005-10-13 | スミスクライン・ビーチャム・コーポレイション | ベンゾオキサジンおよびベンゾオキサジノン置換トリアゾール |
| US7378415B2 (en) | 2004-09-30 | 2008-05-27 | Roche Palo Alto Llc | Benzoxazine and quinoxaline derivatives and uses thereof |
| US7790726B2 (en) * | 2005-08-16 | 2010-09-07 | Chemocentryx, Inc. | Monocyclic and bicyclic compounds and methods of use |
| US20080064871A1 (en) | 2006-05-26 | 2008-03-13 | Japan Tobacco Inc. | Production Method of Nitrogen-Containing Fused Ring Compounds |
| US9604926B2 (en) * | 2007-08-16 | 2017-03-28 | The University Of Mississippi | Highly selective sigma receptor radioligands |
| US8686008B2 (en) * | 2007-08-16 | 2014-04-01 | The University Of Mississippi | Highly selective sigma receptor ligands |
| CN101224207A (zh) | 2007-10-12 | 2008-07-23 | 中国科学院上海有机化学研究所 | 具有诱导自吞噬治疗错误折叠蛋白聚集所致疾病的药物及其筛选方法 |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| PT2266989E (pt) | 2008-03-31 | 2015-11-23 | C&C Res Lab | Derivados heterocíclicos |
| MX2011011875A (es) | 2009-05-08 | 2011-12-08 | Astellas Pharma Inc | Compuesto de carboxamida heterociclica diamino. |
| WO2011059839A1 (en) | 2009-10-29 | 2011-05-19 | Sirtris Pharmaceuticals, Inc. | Bicyclic pyridines and analogs as sirtuin modulators |
| JP2013528180A (ja) * | 2010-05-28 | 2013-07-08 | ジーイー・ヘルスケア・リミテッド | 放射性標識化合物及びその製造方法 |
| WO2012020567A1 (en) * | 2010-08-09 | 2012-02-16 | Raqualia Pharma Inc. | Acyl piperazine derivatives as ttx-s blockers |
| EP2651405A2 (en) * | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| MX352181B (es) | 2012-02-02 | 2017-11-13 | Idorsia Pharmaceuticals Ltd | Compuestos 4- (benzoimidazol-2-il) -tiazol y derivados aza relacionados. |
| JP6510539B2 (ja) * | 2014-01-09 | 2019-05-08 | ザ ジェイ． デヴィッド グラッドストーン インスティテューツ， ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デヴィッド グラッドストーン | 置換ベンゾオキサジン及び関連化合物 |
-
2015
- 2015-01-08 JP JP2016545983A patent/JP6510539B2/ja not_active Expired - Fee Related
- 2015-01-08 CA CA2935944A patent/CA2935944A1/en not_active Abandoned
- 2015-01-08 US US15/110,082 patent/US10087151B2/en active Active
- 2015-01-08 EP EP15735106.5A patent/EP3091984B1/en active Active
- 2015-01-08 WO PCT/US2015/010690 patent/WO2015106025A1/en not_active Ceased
-
2018
- 2018-08-17 US US16/104,840 patent/US10611741B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020532547A5 (enExample) | ||
| DOP2017000057A (es) | Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2 | |
| JP2017528503A5 (enExample) | ||
| NZ598461A (en) | Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases | |
| PE20120119A1 (es) | AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 | |
| UA113157C2 (xx) | Спосіб лікування з використанням селективних інгібіторів bcl-2 | |
| JP2021527638A5 (enExample) | ||
| FI3406609T3 (fi) | Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina | |
| JP2006513202A5 (enExample) | ||
| JP2016538313A5 (enExample) | ||
| CY1114803T1 (el) | Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης | |
| JP2016506386A5 (enExample) | ||
| JP2020502047A5 (enExample) | ||
| JP2014503527A5 (enExample) | ||
| DOP2012000053A (es) | Derivados de (tio) morfolina como moduladores de s1p | |
| RU2013130879A (ru) | Производные оксазолилметилового эфира в качестве агонистов рецептора alx | |
| JP2019529514A5 (enExample) | ||
| PE20191006A1 (es) | Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos | |
| JP2006516626A5 (enExample) | ||
| RU2017128880A (ru) | Производные (r)-2-метил-пиперазина в качестве модуляторов cxcr3 рецептора | |
| JP2012528824A5 (enExample) | ||
| JP2013510155A5 (enExample) | ||
| JP2006504631A5 (enExample) | ||
| JP2016525113A5 (enExample) | ||
| JP2016027024A5 (enExample) |